Pvla Stock Analysis Palvella Therapeutics Inc. Biotech Update Post 1.58 Dip To 122.69 20260401 TXRH Q1 2026 Earnings EPS Beats Estimates Stock Slips Marginally UP Q1 2026 Earnings Steep Loss Reported as Stock Surges on Strategic Progress DV Q1 2026 Earnings EPS Miss Weighs on Shares as Market Digests Profitability Pressure ESTC Q1 2026 Earnings EPS Surprise of 1071 Drives Mixed Market Reaction YQ Q3 2025 Earnings Negative EPS and Stock Decline Amid Ongoing Challenges